ST14 and B-cell non-Hodgkin lymphoma: Our novel antibody against activated matriptase, overexpressed in B-cell lymphoma and epithelial tumors and involved in tumorogenesis, invasiveness and metastasis (27–29), conjugated with the tubulin binding, mitotic inhibitor toxin, monomethyl auristatin E (MMAE), demonstrates that activated matriptase is a bonafide target for use with antibodies that recognize activated matriptase, armed with a toxin.